CytomX Therapeutics Inc Shares Near 52-Week Low - Market Mover

The shares closed 1.8% above its 52-week low of $5.69, with trading volume lower than its 30 day average

Jul 17, 2021 by Kwhen Finance Editors

CytomX Therapeutics Inc Shares Near 52-Week Low - Market Mover
CytomX Therapeutics Inc (CTMX) shares closed today at 1.8% above its 52 week low of $5.69, giving the company a market cap of $376M. The stock is currently down 11.6% year-to-date, down 32.0% over the past 12 months, and down 45.8% over the past five years. This week, the Dow Jones Industrial Average rose 1.6%, and the S&P 500 rose 0.9%.

Trading Activity

  • Trading volume this week was 19.7% lower than the 20-day average.
  • Beta, a measure of the stock’s volatility relative to the overall market stands at 1.1.

Technical Indicators

  • The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.
  • MACD, a trend-following momentum indicator, indicates a downward trend.
  • The stock closed below its Bollinger band, indicating it may be oversold.
  • The stock closed at 2.0% lower than its 5-day moving average, 8.5% lower than its 20-day moving average, and 24.2% lower than its 90-day moving average.

Fundamentals & Catalysts

  • Over the past 12 months the company generated $-58,975,000 in earnings before interest and taxes from $66 million in revenue. It currently holds $393 million in cash and $98 million in debt.
  • Its forward price-to-earnings (P/E) ratio of -5.417899042633061 is higher than its current P/E ratio of -6.21, implying that analysts are expecting a decrease in earnings.
  • The company's price/earnings-to-growth ratio (PEG Ratio), a widely used indicator of a stock's true value while also factoring in expected earnings growth, currently stands at -0.29. A fairly valued company should have a PEG ratio of 1.0. When a company's PEG exceeds 1.0, it's considered overvalued while a stock with a PEG of less than 1.0 is considered undervalued.
  • The company's debt-to-equity ratio, which measures the extent to which it finances its operations through debt, currently stands at 2.97 which means it currently has $2.97 of debt for every $1 of equity. Generally speaking, a debt to equity ratio below 1.0 is seen as relatively safe, while ratios of 2.0 or higher would be considered risky. Some industries are known for having much higher debt to equity ratios than others.
  • The company's price-to-book ratio, which measures the market's valuation of a company relative to its book value, currently stands at 3.19. This means that the stock is trading at a premium of 3 times relative to the company's book value which reflects the total value of a company's assets that shareholders of that company would receive if the company were to be liquidated.
  • The company's price-to-sales ratio, which shows how much the market values every dollar of the company's sales, currently stands at 6.97.
  • The company's enterprise value-to-revenue multiple, which is often used to determine a company's valuation in the case of a potential acquisition, currently stands at 1.07.

P/E

-6.21

EBITDA

$-58,975,000

P/Book

3.19

Mkt Cap

$376M

P/Sales

6.97

Revenue

$66M

EPS (TTM)

-1.22

PEG Ratio

-0.29

EV/Revenue

1.07

Total Cash

$393M

Debt/Equity

2.97

Forward P/E

-5.42

Current Debt

$98M

Gross Profit

$66M

Dividend Date

-

Earnings Date

2021-08-05

Profit Margin

-0.91

Revenue/Share

1.03

Total Revenue

$66M

Enterprise Val

$71M

Put/Call Ratio

0.91

Revenue/Employee

0.00

Market Comparative Performance

  • The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis
  • The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis
  • The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis
NameDoD %ΔYTD %Δ1 Yr %52-Week H %52-Week L %
CytomX Therapeutics Inc-1.5-11.6-32.0-41.04.2
Dow Jones Industrial Average-0.915.432.50.037.3
S&P 500 Index-0.817.037.1-0.438.6
Health Care0.513.123.6-0.529.4

Peer Group Comparative Performance

  • The company's stock price performance year-to-date beats the peer average by -59.3%
  • The company's stock price performance over the past 12 months lags the peer average by 71.5%
NameMKT CAP (USD)P/EYTD %Δ1 Yr %Δ52-Week H %52-Week L %
CytomX Therapeutics IncCTMX-6.2-11.6-32.0-41.04.2
Peer AvgN/A0-28.5-18.6-31.44.1
ORIC Pharmaceuticals IncORIC0-42.5-17.6-52.215.3
Otonomy IncOTIC0-71.4-57.0-73.41.1

This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2021 Kwhen Inc.

Was this content valuable for you?

Tags: